TY - JOUR T1 - Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2019-233432 VL - 13 IS - 6 SP - e233432 AU - Albert D Bui AU - Scott A Helgeson AU - Pramod K Guru AU - Devang K Sanghavi Y1 - 2020/06/01 UR - http://casereports.bmj.com/content/13/6/e233432.abstract N2 - Mortality remains high in septic shock with few new treatment options. Angiotensin II has been recently approved for use in septic shock due to promising results in the ATHOS-3 trial. However, patients with neutropenia were excluded in the trial. This patient population is becoming increasingly common in the intensive care unit as there is an increase in novel biologic therapies and stem cell transplantations for haematological and solid organ malignancies. We present a case of a patient with T-cell acute lymphoblastic leukaemia who received chemotherapy, resulting in neutropenia and septic shock. There was persistent hypotension despite initiating multiple conventional vasopressors. Angiotensin II was attempted with immediate improvement in the blood pressure which resulted in weaning of other vasopressors. This positive haemodynamic response suggests that angiotensin II can successfully be used in neutropenic patients without increasing the overall catecholamine burden of septic shock. ER -